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INTRODUCTION
In	1907,	the	Ramsay	Hunt	syndrome	(RHS)	was	first	
described	by	James	Ramsay	Hunt.	It	is	characterized	
by	acute	facial	nerve	paresis	or	paralysis	accompanied	
by	the	presence	of	herpetic	lesions	on	the	external	ear	
(auricle	and	external	auditory	canal)1.	In	his	original	
classification,	Ramsay	Hunt	stated	that	the	facial	nerve	
was	always	the	first	to	be	affected	in	its	sensory	and/or	
motor	portion;	the	cochleovestibular	symptoms,	such	
as	hearing	 loss,	 tinnitus	or	vertigo	could	also	occur.	
The	RHS	is	caused	by	reactivation	of	 latent	varicel-
la-zoster	virus	(VZV)	in	the	geniculate	ganglion	and	
possibly	in	the	vestibular	and	spiral	ganglia2.
The	VZV	is	a	member	of	human	herpesviruses;	it	
is	 the	etiologic	factor	for	varicella	and	herpes	zoster	
appearance.	Following	the	primary	infection,	VZV	be-
comes	latent	in	the	cells	of	the	dorsal	root	ganglia	and	
may	be	reactivated	after	a	period	of	several	decades;	it	
thus	results	in	the	characteristics	painful	dermatomal	
rash	of	herpes	zoster.	Reactivation is usually associat-	 	 	
ed	with	depressed	cell-mediated	immunity,	such	as	in	
immunosuppressive	therapy	or	HIV	infection	cases3.	
In	herpes	zoster,	the	majority	of	the	morbidity	occurs	
in	 the	 elderly	 and	 is	 accompanied	 by	 complications	
such	as	ophthalmic	zoster	and	post-herpetic	neuralgia.	
The	VZV	is	a	ubiquitous	infection	agent;	in	a	recent	
publication4	 it	 was	 shown	 that	 over	 50%	 of	 young	
children	had	 antibodies	 to	VZV	by	 their	 5th	 of	 their	
age,	and	over	90%	of	adolescents	were	already	sero-
positive	for	VZV.
VZV	has	been	detected	by	means	of	DNA	tests	in	
the	 saliva,	 tears,	 cerebrospinal	 fluid,	 and	 peripheral	
blood	mononuclear	cells,	as	well	as	in	vesicles	of	pa-
tients	 suffering	 RHS5.	 In RHS, VZV was identified	 	 	 	 	
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by	means	of	the	polymerase	chain	reaction	(PCR)	in	
the	geniculate	ganglion	in	the	facial	nerve	sheath6	on	
the	affected	side7.	Moreover, in RHS patients abnor-	 	 	 	
mal	enhancement	of	the	facial	nerve	was	identified	by	
magnetic	resonance	imaging	(MRI)	scan;	this	was	ob-
vious	not	only	in	the	facial	nerve,	but	in	about	70%	of	
cases	in	the	cochleovestibular	nerve	and/or	the	laby-
rinth	 as	well8,9.	Compared	with	 the	 idiopathic	 facial	
paralysis	of	Bell,	the	severity	of	the	facial	paralysis	in	
the	RHS	cases	is	worse	and	its	prognosis	poorer10,11.	
Among	 the	 reported	prognostic	 factors	 affecting	 the	
course	of	RHS	 the	age12,13,	 the	 initial	grading	of	 the	
facial	nerve	palsy12,	diabetes	mellitus13,	essential	hy-
pertension13	and	vertigo13	are	included.	
The	aim	of	 this	 study	was	 to	present	 the	clinical	
data	 of	 15	patients	 suffering	 from	RHS,	 to	 evaluate	
the	efficacy	of	their	treatment	and	to	assess	the	clini-
cal	utility	of	the	electrophysiological	methods	in	the	
prognosis	of	the	disease.
The	study	was	conducted	 in	accordance	with	 the	
Declaration	of	Helsinki	and	the	local	ethics.
MATERIAL-METHODS
Fifteen	RHS	cases	out	of	149	patients	suffering	of	id-
iopathic	unilateral	facial	paresis	or	paralysis	were	ret-
rospectively	analyzed.	The	patients’	age	ranged	from	
22	 to	80	years.	Diagnosis	was	made	on	 the	basis	of	
a)	facial	paresis	or	paralysis,	b)	herpetic	lesions	in	the	
external	ear	(auricle	and	external	auditory	canal)	and	
c)	 increase	of	VZV	titers	detected	by	a	complement	
assay	during	and	after	the	disease.
The	treatment	was	initiated	within	the	first	5	days	
after	 the	 onset	 of	 facial	 paralysis;	 this	 consisted	 of	
intravenous	administration	of	steroids	(prednisolone,	
25mgX3/day,	and	then	tapered	over	10	days	period),	
and/or	oral	administration	of	Acyclovir	800	mg	(five	
times	daily	for	one	week).	In	only	one	case	the	anti-
viral	agent	Valaciclovir	was	orally	administrated	500	
mg	two	times	daily	for	one	week.
The	facial	nerve	function	was	evaluated	on	the	day	
of	admission,	and	then	6	months	later.	The	grading	of	
the	facial	RHS	palsy	was	performed	according	to	the	
House-Brackmann	 grading	 system	 (I-VI)	 (Table	 1).	
The	recovery	of	the	facial	function	was	characterized	
as	«satisfactory»	with	HB	grade	I	and	II	or	«non-sat-
isfactory»	with	HB	grade	III	to	VI.	
Within	the	first	10	days	after	the	onset	of	the	dis-
ease,	the	facial	nerve	function	was	electrophysiologi-
cally	assessed	with	two	tests:	a)	the	nerve	excitability	
test	 (NET)	 and	 b)	 the	 electroneurography	 (ENoG).	
The	Myoton	2	Facial	Nerve	Stimulator	was	used	for	
the	NET	examination.	The	test	was	initially	performed	
on	the	healthy	side	and	then	on	the	affected.	The	cur-
rent	 intensity	 level	 at	which	a	barely	visible	muscle	
twitch	was	elicited	was	determined	as	the	NET	thresh-
old	 respectively	on	both	 sides.	A	 comparison	of	 the	
NET	 threshold	 between	 the	 two	 sides	was	made.	A	
difference	of	3.5	mA	was	defined	as	«normal»;	a	dif-
ference	of	3.5	mA	or	greater	between	 the	 two	 sides	
was	defined	as	«diminished»;	whereas	no	facial	reac-
tion	was	produced	the	cases	were	characterized	as	«no	
response»14.
For	 ENoG,	 the	 surface	 stimulator	 (Amplaid	
MK12)	was	placed	over	the	main	trunk	of	the	facial	
nerve	with	the	anode	just	outside	the	stylomastoid	fo-
ramen	and	 the	 cathode	 in	 front	of	 the	 ear	 lobe.	The	
applied	current	intensity	was	increased	from	zero	to	a	
maximal	level	sufficient	to	evoke	the	myogenic	com-
pound	action	potential.	The	percentage	of	degenerated	
nerve	fibers	was	calculated	by	dividing	the	amplitude	
of	the	myogenic	compound	action	potential	of	the	af-
fected	side	by	that	of	the	normal	side.	The	prognosis	
for	recovery	to	normal	facial	function	was	considered	
poor	 when	 the	 electroneurography	 showed	 greater	
than	90%	neural	degeneration15.
Finally,	an	audiometric	assessment	was	performed	
in	all	the	patients	and	a	pure	tone	audiometry	was	con-
Table 1.	The	House-Brackmann	grading	system	for	the	facial	paresis	or	paralysis.
Grade	I	 Normal	facial	movement.
Grade	II	 Slight	asymmetry	of	facial	movement.
Grade	III	 Obvious	facial	asymmetry;	able	to	close	the	eye	on	the	affected	side.
Grade	IV	 Obvious	facial	asymmetry;	unable	to	close	the	eye	on	the	affected	side
Grade	V	 Only	slight	movement	on	the	face.
Grade	VI	 Absence	of	any	movement	or	tone	of	the	face.
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ducted	 across	 the	 frequencies	 from	250	 to	 8000	Hz	
with	 the	 GSI-61	 audiometer,	 which	 was	 calibrated	
according	to	ISO	389	(International	Organization	for	
Standardization,	1991).
RESULTS
According	to	the	initial	House-Brackmann	facial	nerve	
function	grading,	9	(60%)	patients	were	characterized	
as	grade	V,	1	as	grade	IV,	and	5	as	grade	III.	Four	pa-
tients	exhibited	 facial	paresis	 (or	paralysis)	after	 the	
appearance	of	 the	vesicles,	3	patients	developed	 the	
vesicles	after	the	onset	of	facial	paresis	or	paralysis,	
and	in	8	cases	the	facial	paresis	(or	paralysis)	and	the	
vesicles	appeared	simultaneously.	The	main	localiza-
tions	of	vesicles	are	shown	in	Table	2.	
The	most	common	accompanying	symptoms	were	
cochleovestibular	(73%)	(Table	3).	In	particular,	verti-
go	and	balance	disorder	occurred	in	9	(60%)	patients.	
Tinnitus	was	reported	in	5	patients.	Four	patients	had	
sensorineural	 hearing	 loss	 (moderate	 to	 severe	 sen-
sorineural	hearing	loss	in	2	patients,	one	patient	had	
high-frequency	hearing	 loss;	one	patient	had	 ipsilat-
eral	anacusis).
In	11	(73%)	out	of	the	15	patients,	the	facial	nerve	
recovered	 satisfactorily	 in	 6	 months	 after	 the	 treat-
ment.	However,	 in	4	patients	 the	 recovery	was	non-
satisfactory	 (Figure	2).	Twelve	patients	were	 treated	
with	acyclovir	in	combination	with	steroids	(Table	4);	
9	(75%)	out	of	these	12	patients	recovered	to	grade	I	
and	II.	
In	6	 cases,	 the	 recovery	was	 complete	 (grade	 I);	
one	patient	 remained	 to	grade	V.	 It	was	noticed	 that	
the	 recovery	was	 satisfactory	 in	half	of	 the	 cases	 in	
which	the	initial	facial	paralysis	was	complete	(grade	
V).	According	to	the	history,	the	first	signs	of	recovery	
were	observed	in	the	time	span	of	7	to	30	days	after	
the	onset	of	RHS.	In	the	cases	that	recovered	to	grade	
III	a	certain	form	of	synkinesis	occurred	in	the	long-
term	(after	6	months).	
The	 recovery	was	 satisfactory	 in	 all	 the	 cases	 in	
which	the	NET	was	normal	or	diminished	(Table	5).	
In	4	cases	in	which	the	recovery	was	non-satisfacto-
ry	no	response	was	initially	obtained	in	NET.	In	one	
case,	although	the	ENoG	showed	less	than	90%	of	de-
generation	the	outcome	was	poor	(grade	III),	and	in	4	
Table 2.	Main	localizations	of	the	vesicles	in	RHS.
Localization	 Cases
Pinna	 8	(53%)	(Figure	1)
External	auditory	canal	 2	(13%)
Cervical	region	 2	(13%)	(Figure	1)
Parotid	region	 2	(13%)
Mastoid	area	 1	(6%)	(Figure	1)
Hard	palate	 1	(6%)
Table 3. Distribution	of	accompanying	symptoms	of	RHS	among	the	patient	sample	(n	=	15).
	 n	 %
Cochleovestibular	symptoms	 11		 73
	 -	Vertigo,	instability		 9	 60
Tear	flow	 6	 40
Taste	disorders	 6	 40
Otalgia	 4	 26
Headache	 4	 26
Neck	pain	 3	 20
Numbness	in	the	parotid	region	 2	 13
Vocal	cord	paresis	 1	 		6
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cases	although	the	degeneration	exceeded	the	90%	the	
recovery	was	satisfactory	(grade	I	and	II).		
DISCUSSION
In	this	study,	15	(10%)	out	of	the	149	patients	present-
ing	 with	 unilateral	 acute	 facial	 palsy	 suffered	 from	
RHS.	This	is	consistent	with	the	incidence	reported	in	
other	studies12,16,17,	 in	which	RHS	cases	ranged	from	
3.3%	 to	18%	of	patients	with	unilateral	 acute	 facial	
palsy.	In	the	present	study,	the	RHS	cases	in	relation	
to	Bell’s	(idiopathic)	palsy	cases	were	9:1.
In	10	out	of	the	15	patients	the	vesicles	were	local-
ized	on	 the	 external	 ear.	The	first	 sign	of	RHS	may	
initially	be	presented	as	erythema	of	 the	auricle18	or	
as	vesicles	on	the	external	ear.	When	the	vesicles	be-
come	apparent	after	the	facial	paralysis	then	the	facial	
paresis	(or	paralysis)	may	be	misdiagnosed	as	Bell’s	
palsy.	There	is	also	a	clinical	condition	not	included	in	
the	present	study	called	«zoster	sine	herpete»,	which	
is	characterized	by	facial	paralysis	in	the	absence	of	
vesicles;	the	condition	is	diagnosed	based	on	a	four-
fold	rise	in	serum	antibody	titre	to	VZV19.
The	 distribution	 of	 major	 symptoms	 of	 RHS	 is	
shown	in	Table	3.	The	vestibular	symptoms	dominated	
over	all	the	other	symptoms.	In	other	studies,	vertigo	
has	been	reported	to	be	a	more	frequent	symptom	and	
occurs	in	a	significant	number	of	patients	with	RHS,	
from	72%20	to	85%21.	It	was	shown	that	in	RHS	both	
the	superior	and	the	inferior	division	of	the	vestibular	
nerve	are	affected22.	Although	hearing	loss	incidence	
in	RHS	was	reported	to	be	high	(85%	of	cases21),	in	
the	present	study	it	occurred	in	only	26%	of	the	cases.	
The	hearing	loss	is	always	of	sensorineural	type16.	
Seventh	 and	 eighth	 cranial	 nerve	 dysfunction	 in	
RHS	 is	 considered	 to	 be	 caused	 primarily	 by	VZV	
neuritis;	secondarily	by	inflammatory	oedema	of	these	
nerves	in	their	course	within	the	temporal	bone1,6.	The	
Figure 1. Vesicles	in	RHS	a)	on	the	pinna	b)	on	the	mastoid	and	cervical	region.
Table 4. Facial	nerve	function	(House-Brackmann	grading	system)	before	and	after	treatment	in	the	4	treatment	regimens.
	 Before	treatment	 After	treatment
	 	n	 III	 IV	 V	 I	 II	 III	 V
Acyclovir	+	steroids	 12	 4	 1	 7	 4	 5	 2	 1
Acyclovir	+	valaciclovir	 1	 1	 	 	 1
Acyclovir	 1	 	 	 1	 	 	 1
Steroids	 1	 	 	 1	 1
Total	 15	 5	 1	 9	 6	 5	 3	 1
Α B
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nerve	oedema	in	the	confined	space	within	the	facial	
canal	or	internal	auditory	meatus	induces	nerve	com-
pression	and	hypoxia,	leading	to	further	degeneration	
of	the	nerves.	Inflammation	and	oedema	of	the	para-
lyzed	 facial	 nerve	 in	 the	 Fallopian	 canal	 have	 been	
demonstrated	 during	 decompression	 surgery	 in	 pa-
tients	with	RHS23.	
The	antiviral	agent	acyclovir	is	a	nucleotide	ana-
logue	 that	 interferes	 with	 herpes	 virus	 DNA	 poly-
merase	 and	 inhibits	 DNA	 replication,	 preventing	
further	proliferation	or	spread	of	VZV.	Moreover,	the	
antiedematous	effect	of	steroids	is	clinically	well	con-
firmed.	Thus,	 the	 combined	 therapy	with	 acyclovir-
steroids	is	expected	to	eliminate	the	oedema,	to	avoid	
immunological	reactions,	and	to	reduce	proliferative	
formations24.	
It	has	been	shown11,16	that	if	RHS	was	not	treated,	
the	recovery	rate	 to	normal	facial	function	was	very	
low	between	21%	and	31%	respectively,	demonstrat-
ing	 the	 poor	 natural	 outcome	 of	 the	 disease.	 In	 our	
study,	 the	 therapeutical	 benefit	 of	 the	 treatment	 for	
RHS	was	proved	as	the	recovery	rate	after	treatment	
was	73%.	In	other	studies,	the	recovery	rate	to	grade	
I	and	II	especially	after	the	combined	therapy	of	acy-
clovir	with	steroids	was	reported	to	range	from	80	to	
85%13,25-27
.	
However,	in	Ko’s	study12	the	recovery	rate	
was	53%.
Murakami	 et	 al26	 supported	 the	 effectiveness	 of	
early	 treatment	 in	 RHS	 in	 a	 sample	 of	 80	 patients;	
they	found	that	if	the	treatment	(prednisone	and	acy-
clovir)	initiated	within	3	days	of	the	onset	of	the	dis-
ease	the	patients	significantly	improved,	compared	to	
the	cases	in	which	the	treatment	was	delayed	for	more	
than	3	days	after	the	onset.	In	the	same	study,	it	was	
demonstrated	that	there	was	no	significant	difference	
in	facial	nerve	outcome	between	intravenous	and	oral	
acyclovir	treatment.	
The	 beneficial	 effect	 of	 the	 combined	 treatment	
of	acyclovir	with	steroids	compared	to	steroids	alone	
was	shown	in	Kinishi	et	al’s27	study	in	which	the	for-
mer	treatment	resulted	in	complete	recovery	to	grade	
I	 in	90%	of	cases	and	 in	 the	 latter	 in	64%	of	cases.	
Inamura	et	al28	reported	no	beneficial	effect	on	facial	
function	 when	 only	 acyclovir	 was	 administered	 in	
RHS.
According	 to	 our	 results	 (Table	 5),	 it	 seems	 that	
the	NET	predicted	better	 the	final	 recovery	 than	 the	
ENoG.	It	is	possible	that	the	nerve	degeneration	was	
better	 determined	 after	 a	minimal	 applied	 electrical	
stimulation	 (NET)	 compared	 to	 a	maximal	 stimula-
tion	(ENoG).	Thus,	a	normal	or	diminished	response	
on	NET	was	 in	 favor	 of	 good	 prognosis	 and	 a	 lack	
of	response	on	NET	could	predict	a	poor	recovery.	In	
a	 recent	 study,	 Ikeda	et	 al29	 advocated	 that	 in	Bell’s	
Figure 2. Non-satisfactory	recovery	6	months	after	the	on-
set	of	RHS	(grade	V	according	to	House-Brackmann sys-	
tem).
Table 5.	Relation	between	electroneurography	(ENoG)	and	nerve	excitability	test	(NET)	results	and	degree	of	recovery	of	
facial	nerve	function	in	RHS.
	 Satisfactory	 Non-satisfactory
ENoG	<90%	+	normal	NET	 5	(cases)	 -	
ENoG	<90%	+	diminished	NET	 2	 -
ENoG	<90%	+	no	response	in	NET	 -	 1
ENoG	>90%	+	normal	NET	 4	 -
ENoG	>90%	+	no response in NET - 3	 	 	 	 	
Total	 11	 4
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palsy,	RHS	and	zoster	sine	herpete,	the	NET	response	
was	an	especially	important	prognostic	factor	of	facial	
paralysis;	in	the	same	study29,	it	was	also	shown	that	
the	poor	recovery	rate	was	only	3%	in	patients	who	
were	normal	on	NET,	and	the	poor	recovery	rate	in-
creased	to	83%	when	the	NET	response	was	absent.	
In	agreement	with	our	results,	it	was	concluded29	that	
an	abnormal	response	on	NET	was	considered	to	be	
a	high	risk	factor	for	the	poor	prognosis	of	facial	pa-
ralysis.
In	conclusion,	a	significant	number	of	RHS	cases	
may	 accompanied	 by	 cochleovestibular	 symptoms	
and	in	particular	vertigo	and	balance	disorder.	Instead	
of	the	low	recovery	rate	reported	for	the	natural	course	
of	RHS11,16,	the	combined	treatment	of	acyclovir	with	
steroids	 resulted	 in	 satisfactory	 recovery	 in	 75%	 of	
patients.	 Among	 the	 electrophysiological	 tests,	 the	
NET	was	demonstrated	to	be	the	most	useful	method	
in	the	prognostication	of	RHS.
ΠΕΡΙΛΗΨΗ:	Το	σύνδρομο	Ramsay	Hunt	(RHS)	χαρακτηρίζεται	από	περιφερική	πάρεση	ή	παράλυση	του	προ-
σωπικού	νεύρου	σε	συνδυασμό	με	την	εμφάνιση	φυσαλιδώδους	εξανθήματος	στο	έξω	αυτί.
Υλικό-Μέθοδοι: Αξιολογήθηκαν	15	ασθενείς	που	έπασχαν	από	RHS.	Σε	όλους	τους	ασθενείς	έγινε	λήψη	ιστορικού,	κλινική	
εξέταση	και	στη	συνέχεια	υποβλήθηκαν	σε	αγωγή	με	στεροειδή	και	ακυκλοβίρη.	Για	την	εκτίμηση	της	λειτουργίας	του	
προσωπικού	νεύρου	χρησιμοποιήθηκε	το	σύστημα	ταξινόμησης	κατά	House-Brackmann	(HB	I-VI)	καθώς	και	οι	ηλεκτρο-
φυσιολογικές	εξετάσεις	της	δοκιμασίας	ερεθιστότητας	(NET)	και	ηλεκτρονευρονογραφίας.
Αποτελέσματα: Στο	RHS,	τα	πιο	συχνά	συνοδά	συμπτώματα	ήταν	από	το	αιθουσοκοχλιακό	σύστημα	(73%)	και	κυρίως	η	
εμφάνιση	ιλίγγου	και	διαταραχής	της	ισορροπίας.	�	συνδυασμένη	θεραπεία	της	ακυκλοβίρης	και	των	στεροειδών	είχε	ως	
αποτέλεσμα	την	μεγάλη	βελτίωση	της	λειτουργίας	του	προσωπικού	νεύρου	στο	75%	των	περιπτώσεων.	�	ανάνηψη	ήταν	σε	
όλες	τις	περιπτώσεις	ανάλογη	των	αποτελεσμάτων	του	NET.	�	εξέλιξη	της	παράλυσης	δεν	ήταν	ικανοποιητική	σε	τέσσερις	
περιπτώσεις	στις	οποίες	το	ΝΕΤ	ήταν	καταργημένο.	
Συμπέρασμα: Στο	RHS	είναι	πιθανόν	να	λαμβάνουν	χώρα	νευρίτιδα	και	οίδημα	μέσα	στον	έσω	ακουστικό	πόρο,	τα	οποία	
προκαλούν	πάρεση	ή	παράλυση	του	προσωπικού	νεύρου	και	συμπτώματα	από	το	αιθουσοκοχλιακό	σύστημα.	Γι’	αυτόν	το	
λόγο,	για	την	θεραπευτική	αντιμετώπιση	του	RHS	συνιστάται	η	συνδυασμένη	αγωγή	των	αποιδηματικών	στεροειδών	με	την	
αντιική	ακυκλοβίρη.	�	εξέταση	με	το	NET	είναι	η	πιο	ενδεδειγμένη	ως	προγνωστική	μέθοδος	γι’	αυτό	το	σύνδρομο.	
Λέξεις Κλειδιά: Σύνδρομο Ramsay Hunt, Ωτικός έρπης ζωστήρας, Παράλυση προσωπικού νεύρου, Ακυκλοβίρη, Στεροειδή.
Το σύνδρομο Ramsay Hunt: Κλινική ανάλυση 15 περιστατικών
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